GB2442615A - Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer - Google Patents

Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer Download PDF

Info

Publication number
GB2442615A
GB2442615A GB0720886A GB0720886A GB2442615A GB 2442615 A GB2442615 A GB 2442615A GB 0720886 A GB0720886 A GB 0720886A GB 0720886 A GB0720886 A GB 0720886A GB 2442615 A GB2442615 A GB 2442615A
Authority
GB
United Kingdom
Prior art keywords
modified release
cancer
treatment
fluorocytidine derivative
release compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB0720886A
Other versions
GB0720886D0 (en
Inventor
Scott Jenkins
Gary Liversidge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US67050705P priority Critical
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Priority to PCT/US2006/013629 priority patent/WO2006110800A1/en
Publication of GB0720886D0 publication Critical patent/GB0720886D0/en
Publication of GB2442615A publication Critical patent/GB2442615A/en
Application status is Pending legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

The invention relates to a multiparticulate modified release composition comprising a fluorocytidine derivative, preferably capecitabine, and a modified release component comprising a modified release coating, a modified release matrix material, or both. Following oral delivery, the composition in operation delivers the fluorocytidine derivative in a pulsatile manner at about six to about twelve hours after administration.
GB0720886A 2005-04-12 2006-04-12 Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer Pending GB2442615A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US67050705P true 2005-04-12 2005-04-12
PCT/US2006/013629 WO2006110800A1 (en) 2005-04-12 2006-04-12 Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer

Publications (2)

Publication Number Publication Date
GB0720886D0 GB0720886D0 (en) 2007-12-05
GB2442615A true GB2442615A (en) 2008-04-09

Family

ID=37087358

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0720886A Pending GB2442615A (en) 2005-04-12 2006-04-12 Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer

Country Status (7)

Country Link
EP (1) EP1874271A4 (en)
JP (1) JP2008535920A (en)
CA (1) CA2604192A1 (en)
DE (1) DE112006000873T5 (en)
ES (1) ES2327195B1 (en)
GB (1) GB2442615A (en)
WO (1) WO2006110800A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
WO2016203358A1 (en) * 2015-06-13 2016-12-22 Intas Pharmaceuticals Ltd. Extended release capecitabine capsules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228398B1 (en) * 1998-11-02 2001-05-08 Elan Corporation, Plc Multiparticulate modified release composition
US6503889B2 (en) * 2000-02-28 2003-01-07 Aventis Pharma S.A. Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
AU721653B2 (en) * 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020019365A1 (en) * 2000-06-02 2002-02-14 Jones Richard E. Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethylene)cytidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228398B1 (en) * 1998-11-02 2001-05-08 Elan Corporation, Plc Multiparticulate modified release composition
US6503889B2 (en) * 2000-02-28 2003-01-07 Aventis Pharma S.A. Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer

Also Published As

Publication number Publication date
GB0720886D0 (en) 2007-12-05
JP2008535920A (en) 2008-09-04
WO2006110800A1 (en) 2006-10-19
DE112006000873T5 (en) 2008-03-06
EP1874271A4 (en) 2012-01-25
ES2327195A1 (en) 2009-10-26
EP1874271A1 (en) 2008-01-09
ES2327195B1 (en) 2010-07-09
CA2604192A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
AU2017204772B2 (en) Compositions and their uses directed to huntingtin
SG173036A1 (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
MX2011005908A (en) Antibodies against human angiopoietin 2.
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
TW200740851A (en) Novel macrocyclic inhibitors of hepatitis C virus replication
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
IL181384A (en) Enantiomerically pure aminoheteroaryl compounds, uses thereof in the manufacture of a medicament and pharmaceutical compositions comprising the same
TW201418263A (en) Oxygen linked pyrimidine derivatives
WO2005067898A3 (en) Improved sustained release compositions for pulmonary administration of insulin
WO2008005511A8 (en) Novel inhibitors of hepatitis c virus replication
WO2007014334A3 (en) Method of treatment or management of stress
MX2012006829A (en) Abuse-resistant formulations.
MXPA05002899A (en) Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same.
SG164368A1 (en) Treatment of cancer
IL182728A (en) Substituted tetracycline compound, said compound being for use as a medicament and a pharmaceutical composition comprising said compound
MX2009006235A (en) Pharmaceutical compositions and their methods of use.
IL184951D0 (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
TW200844108A (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
TN2009000457A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
TW200815006A (en) Stable laquinimod preparations
TW200808781A (en) Substituted piperidines that increase P53 activity and the uses thereof
TW200904454A (en) Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
MXPA05014187A (en) Skin treatment articles and methods.
IL180481A (en) Aryl-pyridine derivatives, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments